Synthesis of classical and nonclassical, partially restricted, linear, tricyclic 5-deaza antifolates

Journal of Medicinal Chemistry

Volumn 45, Issue 23, 2002, Pages 5173-5181

  Gangjee, Aleem ^a   Zeng, Yibin ^a   McGuire, John J ^b   Kisliuk, Roy L ^c  

^a DUQUESNE UNIVERSITY   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIAMINO 5 DEAZA 6,7,8,9 TETRAHYDROPYRIDO[3,4 G]PTERIDINE DERIVATIVE; 2,4 DIAMINO 5 DEAZA 7H 6,7,8,9 TETRAHYDROPYRIDO[3,4 G]PTERIDINE; 2,4 DIAMINO 7 (2,4 DICHLOROBENZYL) 5 DEAZA 6,7,8,9 TETRAHYDROPYRIDO[3,4 G]PTERIDINE; 2,4 DIAMINO 7 (3,4 DICHLOROBENZYL) 5 DEAZA 6,7,8,9 TETRAHYDROPYRIDO[3,4 G]PTERIDINE; 2,4 DIAMINO 7 (3,5 DIMETHOXYBENZYL) 5 DEAZA 6,7,8,9 TETRAHYDROPYRIDO[3,4 G]PTERIDINE; 2,4 DIAMINO 7 (4 METHOXYBENZYL) 5 DEAZA 6,7,8,9 TETRAHYDROPYRIDO[3,4 G]PTERIDINE; 2,4 DIAMINO 7 BENZYL 5 DEAZA 6,7,8,9 TETRAHYDROPYRIDO[3,4 G]PTERIDINE; 2,4 DIAMINO 7 CARBOBENZYLOXY 5 DEAZA 6,7,8,9 TETRAHYDROPYRIDO[3,4 G]PTERIDINE; BENZYL DERIVATIVE; CARBON; DIHYDROFOLATE REDUCTASE; FOLIC ACID ANTAGONIST; FOLYLPOLYGLUTAMATE SYNTHASE; METHOTREXATE; METHOTREXATE DERIVATIVE; N [4 [(2,4 DIAMINO 5 DEAZA 6,7,8,9 TETRAHYDROPYRIDO[3,4 G]PTERIDIN 7 YL)METHYL]BENZOYL]GLUTAMIC ACID; NITROGEN; PIRITREXIM; PTERIDINE DERIVATIVE; RECOMBINANT ENZYME; UNCLASSIFIED DRUG;

ALKYLATION; ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CHEMICAL BOND; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DRUG CONFORMATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME INHIBITION; ENZYME SUBSTRATE COMPLEX; HUMAN; HUMAN CELL; NONHUMAN; SUBSTITUTION REACTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIVISION; CELL LINE; DRUG RESISTANCE, NEOPLASM; ESCHERICHIA COLI; FOLIC ACID ANTAGONISTS; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; METHOTREXATE; MOLECULAR CONFORMATION; PEPTIDE SYNTHASES; PNEUMOCYSTIS; RECOMBINANT PROTEINS; SPECIES SPECIFICITY; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY; TETRAHYDROFOLATE DEHYDROGENASE; TOXOPLASMA; TUMOR CELLS, CULTURED;

EID: 0037038312     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0202369     Document Type: Article

References (54)

1. Presented in part at the 219th National Meeting of the American Chemical Society, San Francisco, CA, April 2000; Paper MEDI 89.
2. Presented in part at the 92nd National Meeting of the American Association for Cancer Research, New Orleans, LA, April 2001; Abstract 1568.
3. Berman, E. M.; Werbel, L. M. The renewed potential for folate antagonists in contemporary cancer chemotherapy. J. Med. Chem. 1991, 34, 479-485.
4. Kisliuk, R. L. The Biochemistry of Folates. In Folate Antagonists as Therapeutic Agents; Sirotnak, F. M., Burchall, J. J., Ensminger, W. D., Montgomery, J. A., Eds.; Academic Press: New York, 1984; pp 1-68.
5. Gangjee, A.; Elzein, E.; Kothare, M.; Vasudevan, A. Classical and nonclassical antifolates as potential antitumor, antipneumocystis and antitoxoplasma agents. Curr. Pharm. Des. 1996, 2, 263-280.
6. Kisliuk, R. L.; Gaumont, Y.; Powers, J. F.; Thorndike, J.; Nair, M. G.; Piper, J. R. Synergistic growth inhibition by combination of antifolates. In Evaluation of Folate Metabolism in Health and Disease; Picciano, M. F., Stokstad, E. L. R., Gregory, J. F., III, Eds.; Alan R. Liss: New York, 1990; pp 79-89.
7. Rosowsky, A. Chemistry and biological activity of antifolates. In Progress in Medicinal Chemistry; Ellis, G. P., West, G. B., Eds.; Elsevier Science Publishers: Amsterdam, 1989; pp 1-252.
8. Slavik, K.; Slavikova, V.; Kolma, Z. Metabolism of folic acid. VI. Preparation of intermediary antimetabolites of folic acid. Collect. Czech. Chem. Commun. 1960, 25, 1929-1937.
9. DeGraw, J. I.; Colwell, W. T.; Kisliuk, R. L.; Gaumont, Y.; Sirotnak, F. M. Synthesis and antifolate properties of 5,10-methylenetetrahydro-8,10-dideazaaminopterin. J. Med. Chem. 1986, 29, 1786-1789.
10. Su, T. L.; Yang, Y. K.; Huang, J. T.; Ren, W. Y.; Watanabe, K. A.; Chou, T. C. Synthesis of 4-[(1,3-diaminopyrrolo[3′,4′:4′,5′]pyrido[2, 3-d]pyrimidin-8-yl)-benzoy]]-l-glutamic acid as potential antifolates. J. Heterocycl. Chem. 1993, 30, 1437-1443.
11. DeGraw, J. I.; Christie, P. H.; Colwell, W. T.; Sirotnak, F. M. Synthesis and antifolate properties of 5,10-Ethano-5,10-dideazaaminopterin. J. Med. Chem. 1992, 35, 320-324.
12. (a) Kisliuk, R. L.; Gaumont, Y.; Kumar, P.; Coutts, M.; Nair, M. G.; Nanavati, N. T.; Kalman, T. I. The effect of polyglutamylation on the inhibitory activity of folate analogs. In Proceedings of the Second Workshop on Folyl and Antifolyl Polyglutamates; Goldman, I. D., Ed.; Praeger: New York, 1985; pp 319-328.
13. (b) McGuire, J. J. Antifolate polyglutamylation in preclinical and clinical antifolate resistance. In Antifolate Drugs: Basic Research and Clinical Practice; Jackman, A. L., Ed.; Humana Press: Totowa, NJ, 1999; pp 339-363.
14. Tsukamoto, T.; Haile, W. H.; McGuire, J. J.; Coward, J. K. Mechanism-based inhibition of human folypolyglutamate synthetase: Design, synthesis, and biomedical characterization of phosphopeptide mimic of the tetrahedral intermediate. Arch. Biochem. Biophys. 1998, 355, 109-118.
15. McGuire, J. J.; Hsieh, P.; Franco, C. T.; Piper, J. R. Folypolyglutamate synthesis inhibition and cytotoxic effects of methotrexate analogs containing 2,omega-diaminoalkanoic acids. Biochem. Pharmacol. 1986, 35, 2607-2613.
16. Sanghani, P. C.; Jackman, A.; Evans, V. R.; Thornton, T.; Hughes, L.; Calvert, A. H.; Moran, R. A Strategy for the Design of Membrane-Permeable Folypoly-γ-glutamate Synthetase Inhibitors: "Bay-Region"-Substituted 2-Desamino-2-methyl-5,8dideazafolate Analogs. Mol. Pharmacol. 1994, 45, 341-351.
17. Werbel, L. M. In Folate Antagonists as Therapeutic Agents; Sirotnak, F. M., Burchall, J. J., Ensminger, W., Montgomery, J. A., Eds.; Academic Press: Orlando, FL, 1984; Vol. 1, pp 261.
18. Allegra, C. J.; Kovcas, J. A.; Drake, J. C.; Swan, J. C.; Chabner, B. A.; Masur, H. Activity of antifolates against the pneumocystis carinii dihydrofolate reductase and identification of a potent new agent. J. Exp. Med. 1987, 165, 926-927.
19. Kovcas, J. A.; Allegra, B. A.; Chabner, B. A.; Swan, J. C.; Drake, M.; Lunde, M.; Parrillo, J. E.; Masur, H. Potent effect of trimetrexate, a lipid-soluble antifolate, against toxoplasma gondii. J. Infect. Dis. 1987, 155, 1027.
20. Kovcas, J. A.; Allegra, J. C.; Swan, J. C.; Drake, J. C.; Parrillo, J. E.; Chabner, B. A.; Masur, H. Potent antipneumocystis and antitoxoplasm activities of piritrexim, a lipid-soluble antifolate. Antimicrob. Agents Chemother. 1988, 32, 430-431.
21. Masur, H.; Polis, M. A.; Tuazon, C. U.; Ogata-Arakaki, D.; Kovcas, J. A.; Katz; Hilt, D.; Simmons, T.; Feuerstein, I.; Lundgren, B.; Lane, H. C.; Chabner, B. A.; Allegra, J. C. Salvage Trial of Trimetrexate-Leucovorin for the Treatment of Cerebral Toxoplasmosis in Patients with AIDS. J. Infect. Dis. 1993, 167, 1422-1423.
22. Champness, J. N.; Achari, A.; Ballantine, S. P.; Bryant, P. K.; Delves, C. J.; Stammers, D. K. The structure of Pneumocytis carinii dihydrofolate reductase to 1.9 å resolution. Structure 1994, 2, 915-924.
23. Gangjee, A.; Devraj, R.; Queener, S. Synthesis and dihydrofolate reductase inhibitory activities of 2,4-diamino-5-deaza and 2,4diamino-5,10-dideaza lipophilic antifolates. J. Med. Chem. 1997, 40, 470-478.
24. Mathews, D. A.; Bolin, J. T.; Burdge, J. M.; Filman, K. W.; Kaufman, B. T.; Bedell, C. R.; Champness, J. N.; Stammers, D. N.; Kraut, J. Dihydrofolate reductase. The stereochemistry of inhibitor selectivity. J. Biol. Chem. 1985, 260, 392-396.
25. Gangjee, A.; Donkor, I. O. Synthesis of substituted tetrahydropyrimido[4,5-b][1,7]naphthyridines as potential antitumor agents. J. Heterocycl. Chem. 1989, 26, 705-708.
26. DeGraw, J. I.; Christie, P. H.; Kisliuk, R. L.; Gaumont, Y.; Sirotnak, F. M. Synthesis and antifolate properties of 10-alkyl5,10-dideaza analogs of methotrexate and tetrahydrofolic Acid. J. Med. Chem. 1990, 33, 673-7.
27. Taylor, E. C.; Skotnicki, J. S.; Fletcher, S. R. Synthesis of D,L7,10-Ethano-5-deazaaminopterin and L-Ethano-5-deazafolic Acid. J. Org. Chem. 1985, 50, 1005-1010.
28. McCabe, P. H.; Milne, N. J.; Sim, G. A. Conformational Study of Bridgehead Lactams. Preparation and X-ray Structural Analysis of 1-Azabicyclo[3.3.1]nonane-2,6-dione. J. Chem. Soc., Perkin Trans. 2 1989, 1459-1461.
29. Josey, A. D.; Dickinson, C. L., Jr.; Dewhirst, K. C.; McKusick, B. C. Trifluoromethylmalononitrile. The reaction of 1,1-dichloro2,2-dicyanoethylene with argentous fluoride. J. Org. Chem. 1967, 32, 1941-1944.
30. Protective Groups in Organic Synthesis; Greene, T. W., Wuts, P. G. M., Eds.; John Wiley & Sons: New York, 1999; pp 579580.
31. Lott, R. S.; Chauhan, V. S.; Stammer, C. H. Trimethylsilyl Iodide as a peptide deblocking agent. J. Chem. Soc., Chem. Commun. 1979, 495-496.
32. Angle, S. R.; Arnaiz, D. O. Stereoselective synthesis of substituted pipecolic acids. Tetrehedron Lett. 1989, 5, 515-518.
33. Chelucci, G.; Falorni, M.; Giacomelli, G. Synthesis of 1-substituted 2-[(2S)-2-Pyrrolidinyl]pyridine from L-Proline. Synthesis 1990, 1121-1122.
34. Anantharamaiah, G. M.; Sivanandaiah, K. M. Transfer Hydrogenation: A convenient method for removal of some commonly used protecting group in peptide synthesis. J. Chem. Soc., Perkin Trans. 1 1977, 490-491.
35. Ihara, M.; Taniguchi, N.; Noguchi, K.; Fukumoto, K. Total synthesis of hydrocinchonidine and hydrocinchonine via photooxygenation of an indole derivative. J. Chem. Soc., Perkin Trans. 1 1988, 1277-1281.
36. Gangjee, A.; Zeng, Y.; McGuire, J. J.; Kisliuk, R. L. Effect of C9-Methyl substitution and C8-C9 conformational restriction on antifolate and antitumor activity of classical 5-substituted 2,4-diaminofuro[2,3-d]pyrimidines. J. Med. Chem. 2000, 43, 3125-3133.
37. E. coli DHFR was kindly provided by Dr. R. L. Blakley, St. Jude Children's Research Hospital, Memphis, TN.
38. P. cariniii DHFR was kindly supplied by Dr. D. Borhani, Southern Research Institute, Birmingham, AL.
39. T. gondii DHFR was kindly supplied by Dr. D. V. Santi, University of California, San Francisco CA.
40. Recombinant human DHFR was kindly supplied by Dr. J. H. Freisheim, Medical College of Ohio, Toledo, OH.
41. (a) Marsham, P. R.; Wardleworth, J. M.; Boyl, F. T.; Hennequin, L. F.; Kimbell, R.; Brown, M.; Jackman, A. L. Design and synthesis of potent non-polyglutamatable quinazoline antifolate thymidylate synthase inhibitors. J. Med. Chem. 1999, 42, 3809-3820.
42. (b) Boyle, F. T.; Matusiak, Z. S.; Hughes, L. R.; Slater, A. M.; Stephens, T. C.; Smith, M. N.; Kimbell, R.; Jackman, A. L. Substituted 2-Desamino-2-methylquinazolines. A series of novel antitumour agents. Chemistry and Biology of Pteridines and Folates, Advances in Experimental Medicine and Biology; Ayling, J. E., Nair, M. G., Baugh, C. M., Eds.; Plenum Press: New York, 1995; pp 585-588.
43. Foley, G. F.; Lazarus, H.; Farber, S.; Uzman, B. G.; Boone, B. A.; McCarthy, R. E. Continuous Culture of Lymphoblasts from Peripheral Blood of a Child with Acute Leukemia. Cancer 1965, 18, 522-529.
44. Mini, E.; Srimatkandada, S.; Medina, W. D.; Moroson, B. A.; Carman, M. D.; Bertino, J. R. Molecular and karyological analysis of methotrexate-resistant and -sensitive human leukemic CCRF-CEM cells. Cancer Res. 1985, 45, 317-325.
45. Rosowsky, A.; Lazarus, H.; Yuan, G. C.; Beltz, W. R.; Mangini, L.; Abelson, H. T.; Modest, E. J.; Frei, E., III. Effects of methotrexate esters and other lipophilic antifolates on methotrexate-resistant human leukemic lymphoblasts. Biochem. Pharmacol. 1980, 29, 648-652.
46. McCloskey, D. E.; McGuire, J. J.; Russell, C. A.; Rowan, B. G.; Bertino, J. R.; Pizzorno, G.; Mini, E. Decreased folylpolyglutamate synthetase activity as a mechanism of methotrexate resistance in CCRF-CEM human leukemia sublines. J. Biol. Chem. 1991, 266, 6181-6187.
47. McGuire, J. J.; Coward, J. K. Pteroylpolyglutamates: Biosynthesis, degradation, and function. In Folates and Pterins. Chemistry and Biochemistry of Folates, 1st Ed.; Blakley, R. L., Benkovic, S. J., Eds.; Wiley: New York, 1984; Vol. 1, pp 135190.
48. Rosowsky, A.; Galivan, J.; Beardsley, G. P.; Bader, H.; O'Connor, B. M.; Russelo, O.; Moroson, B. A.; DeYarman, M. T.; Kerwar, S. S.; Freisheim, J. H. Biochemical and biological studies on 2-desamino-2-methylaminopterin, an antifolate the polyglutumates of which are more potent than the monoglutamate against three key enzymes of folate metabolism. Cancer Res. 1992, 52, 2148-2155.
49. We thank the Developmental Therapeutics Program of the National Cancer Institute for performing the in vitro anticancer evaluation.
50. Blakley, R. L. The Biochemistry of Folic Acid and Related Pteridines; Elsevier North-Holland: Amsterdam, 1969; pp 9294.
51. Atkinson, I.; Garrow, T.; Brenner, A.; Shane, B. Human Cytosolic folylpoly-gamma-glutamate synthase; Methods Enzymol. 1997, 281, 134-140.
52. McGuire, J. J.; Hsieh, P.; Coward, J. K.; Bertino, J. R. In vitro methotrexate polyglutamate synthesis by rat liver folylpolyglutamate synthetase and its inhibition by bromosulfophthalein. Adv. Exp. Med. Biol. 1983, 163, 199-214.
53. McGuire, J. J.; Hsieh, P.; Coward, J. K.; Bertino, J. R. Enzymatic synthesis of folylpolyglutamates. Characterization of the reaction and its products. J. Biol. Chem. 1980, 255, 5776-5788.
54. Bolanowska, W. E.; Russell, C. A.; McGuire, J. J. Activation of mammalian folylpolyglutamate synthetase by sodium bicarbonate. Arch. Biochem. Biophys. 1990, 281, 198-203.